The CSL Limited (ASX: CSL) share price continues to struggle this year, but what about the company’s dividends?

After falling to a 52-week low of $240.10 in February, shares in the global biotech leader have travelled sideways.

On Friday, CSL shares closed 1.4% higher at $271.25 apiece.

This is in stark contrast to when the company’s share price registered double-digit gains year-on-year before COVID-19.

Nonetheless, the CSL board has continued to pay dividends to shareholders in times of economic uncertainty.

Let’s dive in to see if the CSL dividends have provided meaningful returns to shareholders over the past five years.

What is CSL’s dividend history?

Here’s a short list I have put together on CSL’s most recent dividend history.

• October 2017 – 92 cents (final)

• April 2018 – 101 cents (interim)

• October 2018 – 128 cents (final)

• April 2019 – 120 cents (interim)

• October 2019 – 145 cents (final)

• April 2020 – 147 cents (interim)

• October 2020 – 147 cents (final)

• April 2021 – 135 cents (interim)

• September 2021 – 159 cents (final)

• April 2022 – 142 cents (interim)

When adding the above amounts, CSL has paid a total dividend of $13.16 per share over the past five years.

However, investors have also seen the CSL share price rise by around 87% during that time.

This means that even a small investment in the global biotech leader’s shares would have reaped some serious benefits.

Currently, CSL has a trailing dividend yield of 1.15%.

CSL share price summary

Despite being one of the best places to park your money over the long term, CSL shares have lost around 8% year to date.

Volatility across global markets due to high inflation levels and rate hikes has been the norm in 2022.

Based on valuation grounds, CSL presides a market capitalisation of approximately $126.09 billion.

The post How much have CSL shares paid in dividends over the last 5 years? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Why this broker is tipping ‘strength in the CSL share price’
• Brokers name 3 ASX shares to buy today
• Why did the CSL share price beat the ASX 200 on Wednesday?
• Broker names 2 of the best ASX 200 shares to buy now
• CSL share price ‘will be significantly bigger from this point’: fundie

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/tuOCMnW

If you’re looking for blue chip shares to buy, then you may want to consider the two listed below that brokers are bullish on.

Here’s what you need to know about these blue chips:

Cochlear Limited (ASX: COH)

The first ASX blue chip share for investors to look at is Cochlear. It is one of the world’s leading hearing solutions companies.

Goldman Sachs is positive on the company, particularly given its improving outlook. In fact, the broker suspects that Cochlear could outperform its guidance in FY 2022.

Goldman commented:

We believe the steady declines in [COVID] hospitalisation rates across key markets, supportive backlog volumes and improved margin trajectory support a much improved picture from here.

As such, we believe current targets for FY22 offer the best chance in several years for COH to deliver at/above the top-end of its guided range (GSe: A$297m).

The broker currently has a buy rating and $237.00 price target on Cochlear’s shares. Based on the current Cochlear share price of $195.16, this implies potential upside of 21% for investors.

Domino’s Pizza Enterprises Ltd (ASX: DMP)

Another blue chip ASX share that brokers say investors should buy is pizza chain operator Domino’s.

Analysts at Morgans are particularly bullish on the company due to its bold store rollout plan. This sees Domino’s aiming to increase its store network to 6,650 stores by 2033, which will be more than double its current network.

Morgans also likes the company due to its defensive qualities in tough times. Though, it concedes that that the near term could be challenging. It explained:

Demand for DMP’s product is likely to remain resilient in times of inflation and slower economic growth. Takeaway food has been one of the most resilient categories of consumer spending during periods of rising inflation. The engine of DMP’s growth is the rollout of new stores.

Although near-term store rollout may be slower than DMP would like, the medium-term opportunity is absolutely undiminished, as evidenced by the reiteration of the 2033 outlook today. DMP has developed a solid platform for inorganic expansion.

The broker has an add rating and $93.00 price target on its shares. Based on the current Domino’s share price of $66.15, this suggests potential upside of 40% for investors.

The post Experts say investors should buy these top blue chip ASX shares appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Own Domino’s shares? Here’s how the company plans to grow through tough times
• 2 beaten down ASX shares named as buys by experts
• Analysts name 2 top ASX 200 shares to buy today
• Down 20% in a year, is the Cochlear share price a bargain buy?
• Experts rate these ASX 200 blue chip shares as buys

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. and Dominos Pizza Enterprises Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/lgKwMTj

While ASX equity and credit markets deal with one of the worst starts to the year on record, it’s been an entirely different story over in investment banking land.

Mergers and acquisitions (M&A) activity has nudged past a number of records in the first half of 2022, according to data compiled by Refinitiv.

Fees alone are up 78% on the prior corresponding period, and deal volume was the highest on record.

Crunching the record numbers

M&A activity blew to new heights in the first half of 2022, according to data presented in the Australia Investment Banking Review First Half 2022 from Refinitiv.

There have been at least four deals announced so far above US$5 billion with a cumulative value of $52 billion, as of June 21.

Data compiled by Refinitiv showed it was a record period for Australia on many fronts.

Overall Australian involvement announced M&A activity amounted to US$103.5 billion in the first half of 2022, a 25.4% increase compared to the first half of last year, making it the highest first-half period since records began in 1980.

The ASX healthcare sector accounted for 23% market share of the deal-making activity by value and totalled US$24.2 billion.

This was underlined by the US$22.1 billion takeover bid for Ramsay Health Care Limited (ASX: RHC) by a consortium led by private equity giant KKR.

It is currently the biggest-ever healthcare deal in Australia, Refinitiv notes.

The energy and power sector followed with 16.6% market value, booking US$17.2 billion of deals, up 26.3% from H1 FY21.

What the report calls “high technology” saw the most number of deals, but captured 13.6% of deal market share.

“Based on preliminary data, Barclays currently leads the Australian involvement announced M&A league tables, with US$36.1 billion in related deal value capturing 34.9% market share,” Refinitiv also said.

Inbound M&A activity is also up 74% from last year, primarily from capital flows from the US. Meanwhile, there are several deals still pending, with only two showing completed on the data provider’s slide deck.

Nevertheless, it shows there’s been a spike in deal-making in Australia at the top end of town, suggesting the outlook for Australia might be quite robust, all things considered.

The post 2022 has seen a record first half for ASX mergers and acquisitions. Here’s the lowdown appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Why I think the Adore Beauty share price is a great buy today
• ‘Need to see cash’: Why these fundies tip big things for the Santos share price
• Brokers name 2 ASX dividend shares to buy next week
• Here’s why brokers rate these ASX growth shares as buys
• Why this broker is tipping ‘strength in the CSL share price’

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ramsay Health Care Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/76hG5an

In my opinion, the Adore Beauty Group Ltd (ASX: ABY) share price is too good to ignore at its current level.

The beauty e-commerce business has seen a very large sell-off – it’s down by more than 70% in 2022.

Plenty of ASX growth shares have seen valuation pain amid inflation and interest rate rises.

While higher interest rates do theoretically pull down on asset prices, I think Adore Beauty has been punished too hard.

I believe there’s a beautiful opportunity here, not just because of the decline but also due to a number of positives for the company.

Revenue

While revenue isn’t the same as profit, I think it’s important to recognise that Adore Beauty is processing a lot of online orders these days, particularly after the e-commerce adoption arising from the COVID-19 lockdowns.

In the latest quarter alone (the FY22 third quarter), Adore Beauty achieved $42.7 million of revenue. This was up 9% year on year.

While the growth rate has slowed, it did still achieve good year-on-year growth in my opinion.

There’s an argument that Adore Beauty’s products could be more defensive than some discretionary spending items. The Adore Beauty CEO Tennealle O’Shannessy said:

Beauty, especially skincare, is unique within the broader retail market and is resilient to economic challenges. Our products are used daily by customers, who consider these items essential and frequently re-purchase. The nature of premium beauty means our customers spend more as they mature on the platform, with returning customers typically contributing more than 70% of total revenue.

Growth initiatives

Over the long term, I think Adore Beauty can continue to grow. It’s the potential growth of the business that makes me believe that it’s currently undervalued.

Firstly, the number of active customers keeps rising. If it can increase its customer base, retain customers, and encourage them to spend more (on Adore Beauty’s website) over a year then that will benefit the ASX share.

In the FY22 third quarter, the company said active customers went up 7% year on year to 880,000, while returning customers increased 47%.

In the FY22 half-year result, annual revenue per active customer rose 5% year on year to $224. I think returning customers spending more will be a key factor for the Adore Beauty share price over time.

Its mobile app now accounts for 10% of revenue and continues to deliver “elevated levels” of engagement, conversion and average order values, according to the company. The launch of its “first” private label products can also help grow, which will hopefully come with higher gross profit margins as well.

The company has a number of podcasts to connect with customers, for a cheaper cost than paid market channels. It also has its own YouTube channel.

Adore Beauty points to successful partnerships with Temple & Webster Group Ltd (ASX: TPW) and 7-Eleven to increase brand awareness.

It’s operating in a “large and growing $11 billion market”, giving a large addressable market to work with.  In 2020, 11.4% of the Australian beauty market was online. That compares to 18.4% in the UK in 2020, so there is potential for a large increase in online adoption.

Increasing scale to help operating leverage

The company is aiming to invest heavily to achieve above-market growth. That’s why its earnings before interest, tax, depreciation and amortisation (EBITDA) margin is expected to be between 2% and 4% in the shorter term.

Adore Beauty itself said that:

In the longer-term, as the business grows, scale benefits are expected to increase operating leverage and deliver further EBITDA margin expansion.

In HY22, the business saw its gross profit margin increase 0.6 percentage points to 33.1% thanks to product margin expansion and brand funding.

The company said that as it grows it will be able to slow its investment in fixed costs, it can forge closer relationships with brands to optimise terms and increase brand funding, and it plans to grow its margin-accretive private label.

The post Why I think the Adore Beauty share price is a great buy today appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• What Adore Beauty, Bubs, Eagers Automotive, and Renascor shares are storming higher
• Why the Adore Beauty share price is jumping but Kogan is falling
• Waiting to start investing in ASX shares? Today could be a brilliant time to do it
• 2 ASX growth shares I’d buy right away with $2,000
• Why is the Adore Beauty share price sliding 6% on Monday?

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Temple & Webster Group Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Adore Beauty Group Limited. The Motley Fool Australia has recommended Adore Beauty Group Limited and Temple & Webster Group Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/So2LgfX